Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of NL003 in Subject With Critical Limb Ischemia(Rutherford 4)

NCT04275323 is registered in ClinicalTrials.gov with Beijing Northland Biotech. Co., Ltd. as lead sponsor.

NCT NCT04275323
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04275323 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of NL003 in Subject With Critical Limb Ischemia(Rutherford 4)
Lead sponsor
Beijing Northland Biotech. Co., Ltd.
Phase
Phase 3
Overall status
Completed
Start date
August 2, 2019
Completion date
June 3, 2024
Enrollment
302 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

arterial occlusive disease, ischemia, peripheral vascular disease, ulcers